New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
12:35 EDTCBST, HSPHospira granted tentative approval for generic daptomycin
Hospira (HSP) was granted tentative approval for generic daptomycin, according to a post to the FDA's website dated June 16. Daptomycin is an antibiotic used in the treatment of infections caused by Gram-positive organisms that is sold under the trade name Cubicin by Cubist Pharmaceuticals (CBST). Reference Link
News For HSP;CBST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
17:38 EDTHSPS&P announces changes to S&P 500 index
Subscribe for More Information
17:18 EDTHSPUnited Continental to replace Hospira in S&P 500 as of 9/2 close
06:55 EDTHSPHospira sees merger closing on or about September 3
Hospira (HSP) said in a regulatory filing that on August 21, Hospira and Pfizer (PFE) received clearance from the U.S. FTC, relating to the pending merger of Hospira with Perkins Holding Company, a wholly-owned subsidiary of Pfizer. All required regulatory approvals have now been secured, though the merger remains conditioned upon the expiration of a post-clearance waiting period in one foreign jurisdiction. Hospira expects the merger to close on or about September 3.
August 25, 2015
09:26 EDTHSPHospira, Cerner expand IV-EMR integration agreement
Subscribe for More Information
August 24, 2015
12:57 EDTHSPFTC requires Pfizer to sell rights to four products as condition of buying Hospira
Subscribe for More Information
08:01 EDTHSPPfizer receives clearance from FTC for Hospira acquisition
Subscribe for More Information
August 20, 2015
05:26 EDTHSPHospira announces approval of Inflectra in Australia
Subscribe for More Information
August 16, 2015
18:01 EDTHSPSenators question Valeant, Hospira on 'artifically inflated' drug prices
Subscribe for More Information
August 14, 2015
08:36 EDTHSPPfizer's pending Hospira acquisition approved by Canadian Competition Bureau
Pfizer (PFE) announced that it received approval from the Canadian Competition Bureau with respect to its pending acquisition of Hospira (HSP). As part of its agreement with the Canadian Competition Bureau, Pfizer has committed to divest certain assets in Canada. "We are pleased the Canadian Competition Bureau concluded its review of the transaction and approved the pending combination of Pfizer and Hospira," said Ian Read, chairman and CEO of Pfizer. "We continue to work cooperatively with the regulatory agencies to obtain the requisite approvals, and continue to expect the transaction to close in the second half of 2015."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use